Study Enrollment

Your details will not be published or shared.

Clinical Trial

A011502: A randomized phase III double blinded placebo-controlled trial of aspirin as adjuvant therapy for node-positive, HER2 negative breast cancer: the ABC trial

The purpose of this study is to compare any good and bad effects of using aspirin after someone has completed the usual chemotherapy, surgery and or radiation therapy for breast cancer. Some studies have suggested that aspirin may lower the risk of breast cancer coming back, but others have not, so we do not know if aspirin will help decrease breast cancer recurrence. This study will evaluate whether patients taking aspirin once per day will have a lower rate of cancer recurrence than patients taking a placebo. A placebo is a tablet that looks like the study drug (aspirin), but contains no medication. This is explained further in the section under the section titled, What are the Study Groups.

Eligibility Criteria

  • - Men or Women ages 18 to 70 - Node positive breast cancer - HER2 negative - Prior chemotherapy and/or endocrine therapy

Contact Information

    Sharad Ghamande, MD

    (706) 721-3992